A flawed Covid-19 study gets the White House’s attention — and the FDA may pay the price

STAT stories you may have missed

STAT’s Matt Herper outlines the high stakes for the FDA as Trump renews his pressure on the agency over hydroxychloroquine. 

Some sobering perspective on telemedicine: It’s convenient, but it’s also a magnet for fraud. 

Hospitals are rapidly running short on the Covid-19 treatment, remdesivir.

Drug makers are back to hiking their prices, according to new data from GoodRx.

Two dozen drug makers have formally launched a $1 billion initiative to invest in new antibiotics.

‘I feel like I am not welcome’: Medical and doctoral students from abroad are grappling with uncertainty from new ICE rules.

This disease detective was thrust onto the frontlines of WHO’s Covid-19 response.